摘要
目的:观察转位蛋白(TSPO)基因在FLT3-ITD/DNMT3A R882双突变急性髓系白血病(AML)疗效评估中的价值。方法:纳入2018年6月至2020年6月在宁波大学附属人民医院血液科住院治疗的初发AML患者76例,其中伴有FLT3-ITD突变34例,伴有DNMT3A R882突变27例,伴有FLT3-ITD/DNMT3A R882双突变15例,对照组为同期住院治疗的免疫性血小板减少症(ITP)患者19例。骨髓穿刺留取骨髓3 ml,常规提取RNA,通过转录组测序方法检测TSPO基因的表达量(使用2^(-ΔΔCT)法计算)。结果:FLT3-ITD单突变组和DNMT3A R882单突变组初诊时TSPO基因表达量分别为2.02±1.04、1.85±0.76,均高于对照组的1.00±0.06,但比较差异无统计学意义(P=0.671,P=0.821);双突变组初诊时TSPO基因表达量为3.98±1.07,明显高于FLT3-ITD单突变组和DNMT3A R882单突变组(P=0.032,P=0.021);双突变组化疗后达到完全缓解的患者,达到完全缓解时的TSPO基因表达量为1.19±0.87,明显低于其初诊时的水平(P=0.011)。结论:TSPO基因或许可以作为评估FLT3-ITD/DNMT3A R882双突变AML治疗疗效的一个指标。
Objective:To observe the clinical significance of translocator proteins (TSPO) gene in the treatment of FLT3-ITD/DNMT3A R882 double-mutated acute myeloid leukemia (AML).Methods:Seventy-six patients with AML hospitalized in the Department of Hematology of the Affiliated People′s Hospital of Ningbo University from June 2018to June 2020 were selected,including 34 patients with FLT3-ITD mutation,27 patients with DNMT3A R882 mutation,15 patients with FLT3-ITD/DNMT3A R882 double mutation,as well as 19 patients with immune thrombocytopenia (ITP)hospitalized during the same period as control group.RNA was routinely extracted from 3 ml bone marrow retained during bone puncture,and TSPO gene expression was detected by transcriptome sequencing (using 2-deltadelta Ct calculation).Results:The expression of TSPO gene in FLT3-ITD group and DNMT3A R882 group at first diagnosis was2.02±1.04 and 1.85±0.76,respectively,which were both higher than 1.00±0.06 in control group,but the differences were not statistically significant (P=0.671,P=0.821).The expression of TSPO gene in the FLT3-ITD/DNMT3A R882group was 3.98±1.07,wich was significantly higher than that in the FLT3-ITD group and DNMT3A R882 group,the differences were statistically significant (P=0.032,P=0.021).The expression of TSPO gene in patients who achieved complete response after chemotherapy in the FLT3-ITD/DNMT3A R882 group was 1.19±0.87,which was significantly lower than that at first diagnosis,and the difference was statistically significant (P=0.011).Conclusion:TSPO gene may be used as an indicator of efficacy in FLT3-ITD/DNMT3A R882 double-mutated AML.
作者
唐善浩
陆滢
张丕胜
陈冬
刘旭辉
杜小红
曹俊杰
李双月
沙科娅
陈列光
庄贤栩
叶佩佩
林丽
裴仁治
TANG Shan-Hao;LU Ying;ZHANG Pi-Sheng;CHEN Dong;LIU Xu-Hui;DU Xiao-Hong;CAO Jun-Jie;LI Shuang-Yue;SHA Ke-Ya;CHEN Lie-Guang;ZHUANG Xian-Xu;YE Pei-Pei;LIN Li;PEI Ren-Zhi(Department of Hematology,The Affiliated People′s Hospital of Ningbo University,Ningbo 315040,Zhejiang Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2023年第1期45-49,共5页
Journal of Experimental Hematology
基金
浙江省医药卫生科技项目(2020KY911)
宁波市自然科学基金(2019A610269)
宁波市鄞州区农业和社会发展科技项目(鄞科2019-63)。
